Effectiveness and Safety of PD-1 Inhibitor Rechallenge After Prior Immunotherapy in Patients Aged ≥ 60 Years with Advanced Non-Small-Cell Lung Cancer: A Single-Center Retrospective Study - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy and Safety of Reinitiating PD-1 Inhibitors Following Previous Immunotherapy in Older Adults (≥ 60 Years) with Advanced Non-Small-Cell Lung Cancer: A Retrospective Analysis from a Single Center

  • By

  • Xiao-Yue Jiang

  • Xin Li

  • Hui Huang

  • Min Pan

  • Qiu-Qiu Chen

  • Chun-Qiao Chen

  • August 29, 2026

Share

Efficacy and Safety of Reinitiating PD-1 Inhibitors in Older Adults with NSCLC

Overview

This study reports a 21.4% objective response rate and an 11.3-month median overall survival for older adults (≥ 60 years) with advanced non-small-cell lung cancer (NSCLC) who underwent PD-1 inhibitor rechallenge. The safety profile aligns with known PD-1 inhibitor toxicities.

Background

Lung cancer is the leading cause of cancer-related mortality, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. As the population ages, the incidence of NSCLC in older adults is increasing.

Data Highlights

No numerical data table available.

Key Findings

  • PD-1 inhibitor rechallenge yielded a 21.4% objective response rate.
  • The median overall survival for patients was 11.3 months.
  • Safety profile was consistent with known PD-1 inhibitor toxicities.
  • Pneumonitis and hepatic enzyme elevations require close monitoring.

Clinical Implications

Clinicians should consider the potential benefits of PD-1 inhibitor rechallenge in older adults with advanced NSCLC.

Conclusion

The findings indicate that PD-1 inhibitor rechallenge can be an option for older adults with advanced NSCLC.

Related Resources & Content

  1. The ASCO Post, 2017 -- Retreatment With Checkpoint Inhibitors May Be Feasible for Some Patients With NSCLC
  2. The ASCO Post, 2014 -- Expert Point of View: Martin Reck, MD, PhD
  3. The ASCO Post, 2025 -- Some Patients With Advanced NSCLC Experience Durable Disease Control After Immunotherapy Discontinuation
  4. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0 | Journal of Clinical Oncology
  5. Frontiers in Oncology — Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study
  6. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0 | Journal of Clinical Oncology
  7. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer - PubMed
  8. PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Original Source(s)

Effectiveness and Safety of PD-1 Inhibitor Rechallenge After Prior Immunotherapy in Patients Aged ≥ 60 Years with Advanced Non-Small-Cell Lung Cancer: A Single-Center Retrospective Study

  • by Xiao-Yue Jiang, Xin Li, Hui Huang, Min Pan, Qiu-Qiu Chen, Chun-Qiao Chen

  • August 29, 2026

Related Content

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • by

  • August 26, 2026

  • 5 min
Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas